A unique case of refractory primary mediastinal B-cell lymphoma with JAK3 mutation and the role for targeted therapy

Haematologica

Volumn 99, Issue 9, 2014, Pages

  Hanna, Diane M T ^a   Fellowes, Andrew ^b   Vedururu, Ravikiran ^b   Mechinaud, Francoise ^a   Hansford, Jordan R ^a  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

JAK inhibitor; PMBCL; Primary mediastinal B cell lymphoma; Refractory; Tofacitinib

Indexed keywords

CD20 ANTIGEN; CD30 ANTIGEN; CD79A ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; JANUS KINASE INHIBITOR; LACTATE DEHYDROGENASE; OFATUMUMAB; OXALIPLATIN; PREDNISOLONE; RITUXIMAB; STAT PROTEIN; TOFACITINIB; VINCRISTINE; ANTINEOPLASTIC AGENT; JAK3 PROTEIN, HUMAN; JANUS KINASE 3; PIPERIDINE DERIVATIVE; PREDNISONE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE;

ADOLESCENT; B CELL LYMPHOMA; BONE MARROW BIOPSY; BURKITT LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; CENTRAL VENOUS PRESSURE; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CRACKLE; DNA EXTRACTION; FEMALE; GENE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERCALCEMIA; JANUS KINASE 3 GENE; LETTER; LYMPH NODE DISSECTION; MEDIASTINUM MASS; MOLECULARLY TARGETED THERAPY; NK T CELL LYMPHOMA; NONHODGKIN LYMPHOMA; POLYMERASE CHAIN REACTION; POSITRON EMISSION TOMOGRAPHY; SEQUENCE ANALYSIS; SYSTOLIC HEART MURMUR; ALLOTRANSPLANTATION; ANTAGONISTS AND INHIBITORS; DRUG RESISTANCE; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MEDIASTINAL NEOPLASMS; METABOLISM; MUTATION; PATHOLOGY; SIGNAL TRANSDUCTION; STEM CELL TRANSPLANTATION;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; JANUS KINASE 3; LYMPHOMA, LARGE B-CELL, DIFFUSE; MEDIASTINAL NEOPLASMS; MOLECULAR TARGETED THERAPY; MUTATION; PIPERIDINES; PREDNISONE; PROTEIN KINASE INHIBITORS; PYRIMIDINES; PYRROLES; SIGNAL TRANSDUCTION; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS; VINCRISTINE;

EID: 84907348482     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2014.108142     Document Type: Letter

References (15)

1. Harismendy O, Schwab RB, Bao L, Olson J, Rozenzhak S, Kotsopoulos SK, et al. Detection of low prevalence somatic mutations in solid tumors with ultra-deep targeted sequencing. Genome Biol. 2011;12(12):R124.
2. Cornejo MG, Kharas MG, Werneck MB, Le Bras S, Moore SA, Ball B, et al. Constitutive JAK3 activation induces lymphoproliferative syndromes in murine bone marrow transplantation models. Blood. 2009;113(12):2746-2754.
3. Matasar MJ, Czuczman MS, Rodriguez MA, Fennessy M, Shea TC, Spitzer G, et al. Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma. Blood. 2013;122(4):499-506.
4. Vyas D, O'Dell KM, Bandy JL, Boyce EG. Tofacitinib: The First Janus Kinase (JAK) inhibitor for the treatment of rheumatoid arthritis. Ann Pharmacother. 2013;47(11):1524-1531.
5. Ortiz-Ibanez K, Alsina MM, Munoz-Santos C. Tofacitinib and other kinase inhibitors in the treatment of psoriasis. Actas Dermosifiliogr. 2013;104(4):304-310.
6. Dymock BW, See CS. Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 - 2012. Expert Opin Ther Pat. 2013;23(4): 449-501.
7. Derenzini E, Younes A. Targeting the JAK-STAT pathway in lym-phoma: a focus on pacritinib. Expert Opin Investig Drugs. 2013;22(6):775-785.
8. Green MR, Monti S, Rodig SJ, Juszczynski P, Currie T, O'Donnell E, et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood. 2010;116(17):3268-3277.
9. Marzec M, Zhang Q, Goradia A, Raghunath PN, Liu X, Paessler M, et al. Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). Proc Natl Acad Sci USA. 2008;105(52):20852-20857.
10. Yamamoto R, Nishikori M, Kitawaki T, Sakai T, Hishizawa M, Tashima M, et al. PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma. Blood. 2008;111(6):3220-3224.
11. Holtick U, Vockerodt M, Pinkert D, Schoof N, Sturzenhofecker B, Kussebi N, et al. STAT3 is essential for Hodgkin lymphoma cell proliferation and is a target of tyrphostin AG17 which confers sensitiza-tion for apoptosis. Leukemia. 2005;19(6):936-944.
12. Steidl C, Gascoyne RD. The molecular pathogenesis of primary mediastinal large B-cell lymphoma. Blood. 2011;118(10):2659-2669.
13. Elliott NE, Cleveland SM, Grann V, Janik J, Waldmann TA, Dave UP. FERM domain mutations induce gain of function in JAK3 in adult T-cell leukemia/lymphoma. Blood. 2011;118(14):3911-3921.
14. Koo GC, Tan SY, Tang T, Poon SL, Allen GE, Tan L, et al. Janus kinase 3-activating mutations identified in natural killer/T-cell lymphoma. Cancer Discov. 2012;2(7):591-597.
15. Cornejo MG, Boggon TJ, Mercher T. JAK3: a two-faced player in hematological disorders. Int J Biochem Cell Biol. 2009;41(12):2376-2379.